Oncolytics Biotech Inc. (ONCY)

[onco_investor]

Bio on Dr Warrander Consulting




http://www.warranderconsulting.com/about-warrander-consulting.asp

Alan Warrander has over 30 years wide-ranging experience and a broad range of contacts in the Pharmaceutical Industry having worked both in Pharma companies and as a Consultant.
Until the end of 2007, Alan was Senior Vice President, Life Sciences at Wood Mackenzie, the global consultancy firm, where he provided consultancy advice and expert scientific opinion to Pharma, Biotech companies, Finance groups and Law firms primarily in the areas of Partnering, Due Diligence and Strategic Planning. Alan was also responsible for the production of a number of Expert Reports on a range of companies in support of potential AIM flotations.
Prior to joining Wood Mackenzie in mid-2005, Alan held the position of Director of Global Licensing with AstraZeneca where he covered all aspects of partnering (Evaluation, Due Diligence and Transaction Management) for the Oncology and Infection Therapeutic Areas. Before moving to Licensing in 1998, for a considerable number of years, Alan led a Drug Metabolism/Pharmacokinetics Unit at ICI/Zeneca Pharmaceuticals and contributed to the development and registration of a number of successful drugs in addition to providing support to Research and Commercial groups across a range of therapeutic areas. Prior to joining ICI, he had previous experience in the Drug Metabolism department of Hoechst UK and as head of the Drug Metabolism section at Sterling-Winthrop.
His academic background is in Drug Metabolism, with a PhD from Birmingham University and a BSc in Chemistry and Biochemistry from St Andrews.
He is a well-recognized conference speaker and trainer, presenting on various aspects of Partnering and Due Diligence at a range of international conferences and workshops.
Warrander Consulting has very wide connections across the industry on a global basis and associations with an extensive network of consultants covering virtually every aspect of drug discovery, development, registration, business development and commercialization.